NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free OCUL Stock Alerts $6.05 +0.41 (+7.27%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$5.81▼$6.1650-Day Range$4.20▼$10.8352-Week Range$2.00▼$11.31Volume1.99 million shsAverage Volume3.50 million shsMarket Capitalization$937.08 millionP/E RatioN/ADividend YieldN/APrice Target$15.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ocular Therapeutix alerts: Email Address Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside150.7% Upside$15.17 Price TargetShort InterestBearish13.61% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews Sentiment-0.25Based on 17 Articles This WeekInsider TradingAcquiring Shares$7 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.91) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.55 out of 5 starsMedical Sector308th out of 928 stocksPharmaceutical Preparations Industry136th out of 431 stocks 3.4 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 4 research reports in the past 90 days.Read more about Ocular Therapeutix's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.61% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Ocular Therapeutix has recently increased by 43.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 1.0 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Ocular Therapeutix this week, compared to 4 articles on an average week.Search InterestOnly 16 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($0.91) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ocular Therapeutix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesMay 15 at 2:59 AM | finance.yahoo.comOcular Therapeutix Inc Reports First Quarter 2024 EarningsMay 13 at 1:52 AM | americanbankingnews.comHC Wainwright Analysts Decrease Earnings Estimates for Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 12 at 6:06 AM | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 7%May 11, 2024 | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 10, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) PT Lowered to $22.00May 10, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00May 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong ProspectsMay 7, 2024 | washingtonpost.comOcular Therapeutix: Q1 Earnings SnapshotMay 7, 2024 | investorplace.comOCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comOcular Therapeutix™ Reports First Quarter 2024 ResultsMay 7, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2024 | markets.businessinsider.comOcular Therapeutix is about to announce its earnings — here's what to expectMay 6, 2024 | globenewswire.comOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | msn.comEyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goalMay 5, 2024 | stockhouse.comOcular Therapeutix(TM) To Present at Two Ophthalmology Meetings, May 4-9, 2024May 3, 2024 | globenewswire.comOcular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024May 1, 2024 | globenewswire.comOcular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024April 24, 2024 | fool.com2 Small-Cap Growth Stocks With Room To RunApril 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD PotentialApril 19, 2024 | msn.comBaird sees weakness in Ocular shares as "overdone"April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)April 18, 2024 | marketwatch.comOcular Therapeutix Shares Dive on Axpaxli Trial ResultsApril 18, 2024 | markets.businessinsider.comOcular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDRApril 18, 2024 | seekingalpha.comOcular marks early-stage trial win for diabetic retinopathy candidateApril 18, 2024 | globenewswire.comOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathySee More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/15/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$15.17 High Stock Price Target$22.00 Low Stock Price Target$7.00 Potential Upside/Downside+150.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-192.61% Pretax Margin-192.61% Return on Equity-76.64% Return on Assets-36.33% Debt Debt-to-Equity Ratio0.16 Current Ratio21.39 Quick Ratio21.29 Sales & Book Value Annual Sales$58.44 million Price / Sales16.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book2.30Miscellaneous Outstanding Shares154,890,000Free Float146,370,000Market Cap$937.08 million OptionableOptionable Beta1.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 56)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Jeffrey S. Heier M.D. (Age 63)Chief Scientific Officer Comp: $84.88kDr. Rabia Gurses Ozden M.D. (Age 55)Chief Medical Officer Comp: $621.39kDr. Pravin U. Dugel M.D. (Age 60)Executive Chairman Dr. Karen-Leigh Edwards M.B.A.Ph.D., Chief Operations OfficerDr. Peter K. Jarrett Ph.D. (Age 67)Chief Technology Officer Mr. Philip C. Strassburger Esq. (Age 64)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMore ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTLiquidiaNASDAQ:LQDACentessa PharmaceuticalsNASDAQ:CNTAOPKO HealthNASDAQ:OPKBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Bought 17,251 shares on 5/14/2024Ownership: 0.037%EntryPoint Capital LLCBought 15,312 shares on 5/14/2024Ownership: 0.010%Ameritas Investment Partners Inc.Bought 3,257 shares on 5/13/2024Ownership: 0.007%Vanguard Group Inc.Bought 2,117,029 shares on 5/10/2024Ownership: 4.676%Banco Santander S.A.Sold 332,280 shares on 5/10/2024Ownership: 0.135%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks. What is Ocular Therapeutix's stock price target for 2024? 6 brokerages have issued 1-year target prices for Ocular Therapeutix's stock. Their OCUL share price targets range from $7.00 to $22.00. On average, they expect the company's stock price to reach $15.17 in the next twelve months. This suggests a possible upside of 150.7% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts. How have OCUL shares performed in 2024? Ocular Therapeutix's stock was trading at $4.46 at the start of the year. Since then, OCUL stock has increased by 35.7% and is now trading at $6.05. View the best growth stocks for 2024 here. When is Ocular Therapeutix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our OCUL earnings forecast. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings results on Monday, March, 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, hitting analysts' consensus estimates of ($0.28). The biopharmaceutical company had revenue of $14.80 million for the quarter, compared to the consensus estimate of $15.31 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 76.64% and a negative net margin of 192.61%. What ETFs hold Ocular Therapeutix's stock? ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.68%), Deltec Asset Management LLC (1.59%), Essex Investment Management Co. LLC (0.24%), Banco Santander S.A. (0.13%), BNP Paribas Financial Markets (0.12%) and American International Group Inc. (0.04%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUL) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersBiden to Drop BOMBSHELL June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
